Tagrix Tablet
Osimertinib
80mg
Beacon Pharmaceuticals Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 35649.76 NPR |
Indications
Tagrix Tablet is used for:
Non-small Cell Lung Cancer
Indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Adult Dose
Non-small Cell Lung Cancer
80 mg once daily.
Hepatic impairment
Mild (TB
Child Dose
Renal Dose
Administration
May be taken with or without food: Take at the same time each day. Swallow whole, do not crush/split/chew.
For patients w/ swallowing difficulties, tab may be dispersed in 50 mL non-carbonated water & stir w/o crushing until dispersed. Drink immediately. Rinse glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via nasogastric tube by using 15 mL for initial dispersion & 15 mL for residue rinses. The tube should be flushed w/ water after administration. Soln should be administered w/in 30 min of the addition of tab to water.
Contra Indications
Precautions
Determine EGFR T790M mutation status prior to treatment. Interstitial lung disease (eg, pneumonitis). Avoid use in patients w/ congenital long QT syndrome. Severe & end-stage renal impairment. May affect ability to drive or operate machinery.
Women of childbearing potential not using contraception. Use effective contraception for at least 6 wk for females & 4 mth for males. Not recommended during pregnancy. Lactation.
Based on its mechanism of action and animal data, Osimertinib can cause fetal harm when administered to a pregnant woman. There are no available data on Osimertinib use in pregnant women. Pregnant women should be advised of the potential risk to a fetus.
There are no data on the presence of Osimertinib in human milk, the effects of Osimertinib on the breastfed infant or on milk production. Lactating woman should be advised not to breastfeed during treatment.
Pregnancy-Lactation
Interactions
Decreased exposure w/ strong CYP3A4 inducers (eg, phenytoin, rifampicin, carbamazepine, St. John's wort). May increase AUC & Cmax of rosuvastatin. May increase the exposure of BCRP substrates. Decreased AUC & Cmax of simvastatin.
Adverse Effects
Side effects of Osimertinib :
>10%
Lymphopenia (63%),Thrombocytopenia (54%),Anemia (44%),Diarrhea (42%),Rash (41%),Neutropenia (33%),Dry skin (31%),Hyponatremia (26%),Nail toxicity (25%),ypermagnesemia (20%),Eye disorders (18%),Nausea (17%),Decreased appetite (16%),Constipation (15%),Pruritus (14%),Fatigue (14%),Cough (14%),Back pain (13%),Stomatitis (12%)
1-10%
Headache (10%),Venous thromboembolism (7%),Pneumonia (4%),Interstitial lung disease/pneumonitis (3.3%),QTc increased from baseline >60 msec (2.7%),Cardiomyopathy (1.4%)
<1%
Keratitis
Mechanism of Action
Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type. In cultured cells and animal tumor implantation models, osimertinib exhibited anti-tumor activity against non-small cell lung cancer (NSCLC) lines harboring EGFR-mutations (T790M/L858R, L858R, T790M/exon 19 deletion, and exon 19 deletion) and, to a lesser extent, wild-type EGFR amplifications.
Note
Tagrix 80mg Tablet manufactured by Beacon Pharmaceuticals Ltd.. Its generic name is Osimertinib. Tagrix is availble in Nepal.
Farmaco Nepal drug index information on Tagrix Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.